https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Fri, 28 Jan 2022 09:18:39 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png https://mirror.vjregenmed.com 32 32 https://mirror.vjregenmed.com/video/kn-qodpt6bo-targeting-solid-tumors-spear-t-cells-hla-independent-tcrs/ Sat, 03 Jul 2021 11:01:11 +0000 http://13.40.107.223/video/kn-qodpt6bo-targeting-solid-tumors-spear-t-cells-hla-independent-tcrs/ Jo Brewer, PhD, Adaptimmune, Philadelphia, PA, provides an overview of the specific peptide enhanced affinity receptor (SPEAR) T-cell platform, which involves genetically engineering T-cell receptors to enhance their ability to recognize specific peptide antigens, thus increasing the immune system’s ability to recognize and target cancer cells. This technology is currently being investigated in clinical trials for the treatment of a range of solid tumors, such as the Phase II SPEARHEAD-1 trial (NCT04044768) in patients with synovial sarcoma. A novel human leukocyte antigen (HLA)-independent T-cell receptor (TCR) platform is also currently in development, which would allow the targeting of tumor cells without the need for HLA subtyping. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

]]> https://mirror.vjregenmed.com/video/adxuzr-4ok-spearhead-1-adp-a2m4-in-synovial-sarcoma-and-mrcls/ Sat, 03 Jul 2021 11:01:10 +0000 http://13.40.107.223/video/adxuzr-4ok-spearhead-1-adp-a2m4-in-synovial-sarcoma-and-mrcls/ Jo Brewer, PhD, Adaptimmune, Philadelphia, PA, introduces the ongoing Phase II SPEARHEAD-1 trial (NCT04044768), assessing the efficacy and safety of ADP-A2M4 in patients with synovial sarcoma or myxoid/round cell liposarcoma (MRCLS). The ADP-A2M4 SPEAR T-cell therapy targets the MAGE- A4 antigen presented by HLA-A2+ patients. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

]]>